Visualitzant CEMCAT - Articles científics per títol
Ara mostrant els elements 86-105 d 106
-
Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets: A MAGNIFY-MS Substudy
(Lippincott Williams & Wilkins, 2023-01) -
Teriflunomide and Epstein–Barr virus in a Spanish multiple sclerosis cohort: in vivo antiviral activity and clinical response
(Frontiers Media, 2023-09-29) -
The OSCAR-MP Consensus Criteria for Quality Assessment of Retinal Optical Coherence Tomography Angiography
(Wolters Kluwer Health, 2023-11) -
The potential of serum neurofilament as biomarker for multiple sclerosis
(Oxford University Press, 2021-10) -
The state of multiple sclerosis: current insight into the patient/health care provider relationship, treatment challenges, and satisfaction
(Dove Medical Press, 2016-12-22) -
Therapeutic inertia in the management of neuromyelitis optica spectrum disorder
(Frontiers Media, 2024-02-21) -
Traffic Lights Intervention Reduces Therapeutic Inertia: A Randomized Controlled Trial in Multiple Sclerosis Care
(SAGE Publications, 2019-06-21) -
Transcriptome and Function of Novel Immunosuppressive Autoreactive Invariant Natural Killer T Cells That Are Absent in Progressive Multiple Sclerosis
(Lippincott Williams & Wilkins, 2021-11) -
Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity
(Lippincott, Williams & Wilkins, 2022-11) -
Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom
(Lippincott Williams & Wilkins, 2021-07) -
Use of smartphone-based remote assessments of multiple sclerosis in Floodlight Open, a global, prospective, open-access study
(Nature Portfolio, 2024-01-02) -
Vaccine Safety and Immunogenicity in Patients With Multiple Sclerosis Treated With Natalizumab
(American Medical Association, 2024-04-01) -
Views of Multiple Sclerosis Patients About Key Elements for a Decision Aid: A Qualitative Study
(Wolters Kluwer Health, 2023-10)